trial · primary record
Atezolizumab
Bladder Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2026-12 |
| Primary endpoint | Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate. |
| Registry ID | NCT02989584 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:37.699Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02989584
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.